Arenicin-1 vs Cotadutide
Head-to-head comparison of Arenicin-1 (Arenicin-1) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Arenicin-1 | Cotadutide |
|---|---|---|
| Category | Marine-Derived | Weight Management |
| Full Name | Arenicin-1 | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | 2079 Da | ~4,700 Da |
| Half-Life | n/a | Approximately 24 hours |
| Amino Acids | 21 | 37 |
| Typical Dose | n/a | 0.3-3 mg daily in clinical studies |
| Route | preclinical | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 76 | 18 |
| Research Status | Pre-clinical | Clinical |
Arenicin-1 Benefits
- ✓antimicrobial
- ✓anti-biofilm
- ✓membrane-active
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Arenicin-1 Dosing
bacterial infection|biofilm disruption
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Arenicin-1 Side Effects
- ⚠Arenicola marina
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Arenicin-1
Marine annelid peptide with strong preclinical antibacterial activity and a stable structural motif that is useful for peptide engineering.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.